Answers are grounded in this paper and cite their sources.
Provides a clinical overview of the urgent reversal of vitamin K antagonists in patients presenting with severe bleeding such as intracranial hemorrhage.
### What you need to know A 78 year old man is brought to the emergency department after collapsing. He is drowsy with signs of a left hemiparesis. Computed tomography of the brain shows an intracranial bleed. He has a history of atrial fibrillation, and he has been taking warfarin (INR target 2-3) for several years. His wife says he started a course of antibiotics for a chest infection a week before. His INR is 8. Warfarin is a vitamin K antagonist (fig 1) and a coumarin (more accurately 4-hydroxycoumarin) derivative. It is the most commonly used vitamin K antagonist in the world.1 The main uses for vitamin K antagonists are prevention of stroke in patients with atrial fibrillation, and prevention of thrombosis in those with previous venous thromboembolism or with mechanical heart valves. In some countries, other coumarins are used with a similar action but a shorter (acenocoumarol) or longer (phenprocoumon) half-life. Fig 1 Coagulation factors II (prothrombin), VII, IX, and X, and the physiological anticoagulant proteins C and S, undergo vitamin K-dependent post-translational carboxylation in the liver before secretion into plasma. This step activates the coagulation factors, giving them the ability to bind to calcium. During carboxylation, vitamin K is oxidised to its inactive form vitamin K epoxide, which is regenerated by the enzyme vitamin K epoxide reductase. Vitamin K antagonists act as competitive …
No takes yet. Share an insight, caveat, or question.
Hunt et al. (2018) conducted a review in Vitamin K antagonist-associated bleeding. Prothrombin complex concentrate (PCC) vs. Fresh frozen plasma (FFP) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: